External Quality Assessment Scheme for HIV-1 Drug-Resistance Genotyping in Thailand
External Quality Assessment Scheme for HIV-1 Drug-Resistance Genotyping in Thailand
复制标题
DOI：
10.1089/aid.2017.0299
复制
发表时间：
2018-11-10
影响因子：
1.5
通讯作者：
Motomura, Kazushi
中科院分区：
文献类型：
--
作者：
Saeng-aroon, Siriphan;Saipradit, Nonglak;Motomura, Kazushi
HIV-1 耐药菌株的出现和传播可能会影响抗逆转录病毒 (ARV) 治疗的疗效。因此，HIV-1 耐药 (DR) 基因型检测在为 HIV 感染者选择最佳治疗方案方面发挥着重要作用。鉴于测试程序的复杂性和所使用方法的多样性，实验室之间的结果有很大可能存在差异。在泰国，国家外部质量评估 (EQA) 计划评估实验室的 DR 基因型检测表现。在这里，我们评估了 2010-2015 年间实验室在核苷酸测序方面的表现，并比较了 HIV-1 蛋白酶 (PR) 和逆转录酶 (RT) 基因中的耐药相关突变 (DRM)。 12 个组中的 EQA 样本显示 CRF01_AE (85%) 和 B 亚型 (15%) 占主导地位。生成了 14 个实验室数据集：8 个使用 TruGene (TG)，2 个使用 ViroSeq (VS)，4 个使用内部 (IH) 检测。所有IH和VS实验室都有罚分
The efficacy of antiretroviral (ARV) therapy can be compromised by the emergence and transmission of HIV-1 drug-resistant strains. HIV-1 drug-resistance (DR) genotypic testing thus plays an important role in the selection of optimal treatment regimens for HIV-infected individuals. Given the complexities of the testing procedures and the variety of approaches used, there is considerable potential for results to vary between laboratories. In Thailand, the national External Quality Assessment (EQA) scheme assesses the DR genotype testing performance of laboratories. Here, we evaluated the performance of laboratories in nucleotide sequencing and compared drug-resistance-associated mutations (DRMs) in the HIV-1 protease (PR) and reverse transcriptase (RT) genes during 2010-2015. The EQA samples in the 12 panels showed predominance for the CRF01_AE (85%) and subtype B (15%). Fourteen laboratory datasets were generated: eight using TruGene (TG), two using ViroSeq (VS), and four using in-house (IH) assays. All IH and VS laboratories had penalty scores